Suppr超能文献

改善治疗策略的获益与风险沟通:局限性前列腺癌治疗决策辅助工具

Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions.

作者信息

Hoffman Richard M

机构信息

Medicine Service, Albuquerque Veterans Affairs Medical Center, 1501 San Pedro Dr. SE, Albuquerque, NM 87108, USA.

出版信息

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):197-201. doi: 10.1093/jncimonographs/lgs023.

Abstract

Treatment decisions for localized prostate cancer are preference sensitive. The optimal treatment strategy is unknown, and active treatment is not always necessary. Choosing among the various options involves tradeoffs between cancer control and complications that affect quality of life. A shared decision-making process, particularly facilitated by a decision aid, can help a patient make an informed decision that is concordant with his values and preferences. Studies have shown that informed patients are more willing to forego aggressive treatment, but much work is needed to develop and evaluate high-quality decision aids that accurately portray active surveillance. The research agenda for decision aids includes evaluating content elements and format, timing and setting for delivery, the quality of the decision-making process, and the effects of decision support on treatment selection (which will occur repeatedly for men opting for active surveillance) and quality of life.

摘要

局限性前列腺癌的治疗决策具有偏好敏感性。最佳治疗策略尚不清楚,且并非总是需要积极治疗。在各种治疗方案中进行选择需要在癌症控制与影响生活质量的并发症之间进行权衡。一个共同决策的过程,特别是在决策辅助工具的帮助下,可以帮助患者做出符合其价值观和偏好的明智决策。研究表明,了解情况的患者更愿意放弃积极治疗,但仍需要开展大量工作来开发和评估能够准确描述主动监测的高质量决策辅助工具。决策辅助工具的研究议程包括评估内容要素和形式、提供的时间和环境、决策过程的质量,以及决策支持对治疗选择(对于选择主动监测的男性患者来说,这一过程会反复出现)和生活质量的影响。

相似文献

2
5
Informed Decision Making: Assessment of the Quality of Physician Communication about Prostate Cancer Diagnosis and Treatment.
Med Decis Making. 2015 Nov;35(8):999-1009. doi: 10.1177/0272989X15597226. Epub 2015 Aug 24.
6
Evolution of a CDC Public Health Research Agenda for Low-Risk Prostate Cancer.
Am J Prev Med. 2015 Dec;49(6 Suppl 5):S483-8. doi: 10.1016/j.amepre.2015.08.016.
7
Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
Semin Urol Oncol. 2002 Feb;20(1):10-7. doi: 10.1053/suro.2002.30393.
8
Quality of life in men undergoing active surveillance for localized prostate cancer.
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):242-9. doi: 10.1093/jncimonographs/lgs026.
9
Patient decision aids for prostate cancer treatment: a systematic review of the literature.
CA Cancer J Clin. 2009 Nov-Dec;59(6):379-90. doi: 10.3322/caac.20039. Epub 2009 Oct 19.

引用本文的文献

2
Informed decision-making based on a leaflet in the context of prostate cancer screening.
Patient Educ Couns. 2019 Aug;102(8):1483-1489. doi: 10.1016/j.pec.2019.03.009. Epub 2019 Apr 13.
3
Decision-making processes among men with low-risk prostate cancer: A survey study.
Psychooncology. 2018 Jan;27(1):325-332. doi: 10.1002/pon.4469. Epub 2017 Jul 13.
4
Physicians' perspectives on the informational needs of low-risk prostate cancer patients.
Health Educ Res. 2017 Apr 1;32(2):134-152. doi: 10.1093/her/cyx035.
6
Evolution of a CDC Public Health Research Agenda for Low-Risk Prostate Cancer.
Am J Prev Med. 2015 Dec;49(6 Suppl 5):S483-8. doi: 10.1016/j.amepre.2015.08.016.
7
Treatment decisions for localized prostate cancer: a concept mapping approach.
Health Expect. 2015 Dec;18(6):2079-90. doi: 10.1111/hex.12175. Epub 2014 Feb 9.
8
Patient-physician communication about early stage prostate cancer: analysis of overall visit structure.
Health Expect. 2015 Oct;18(5):1757-68. doi: 10.1111/hex.12168. Epub 2013 Dec 22.

本文引用的文献

1
Radical prostatectomy versus observation for localized prostate cancer.
N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162.
2
Decision aids for people facing health treatment or screening decisions.
Cochrane Database Syst Rev. 2011 Oct 5(10):CD001431. doi: 10.1002/14651858.CD001431.pub3.
3
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
N Engl J Med. 2011 Jul 14;365(2):107-18. doi: 10.1056/NEJMoa1012348.
4
Radical prostatectomy versus watchful waiting in early prostate cancer.
N Engl J Med. 2011 May 5;364(18):1708-17. doi: 10.1056/NEJMoa1011967.
5
Overtreatment of men with low-risk prostate cancer and significant comorbidity.
Cancer. 2011 May 15;117(10):2058-66. doi: 10.1002/cncr.25751. Epub 2010 Nov 29.
6
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.
7
Outcomes of active surveillance for men with intermediate-risk prostate cancer.
J Clin Oncol. 2011 Jan 10;29(2):228-34. doi: 10.1200/JCO.2010.31.4252. Epub 2010 Nov 29.
9
Physician visits prior to treatment for clinically localized prostate cancer.
Arch Intern Med. 2010 Mar 8;170(5):440-50. doi: 10.1001/archinternmed.2010.1.
10
Time trends and local variation in primary treatment of localized prostate cancer.
J Clin Oncol. 2010 Mar 1;28(7):1117-23. doi: 10.1200/JCO.2009.26.0133. Epub 2010 Feb 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验